Ethics Transparency

Transparency Disclosures

Payments to U.S.-Based
Health Care Professionals

Payments to U.S.-Based
Health Care Professionals
Transparency Disclosures

We believe in broad disclosure of financial relationships between physicians and the pharmaceutical industry.

As an early supporter of the Physician Payments Sunshine Act (PPSA), we believe in broad disclosure of financial relationships between physicians and the pharmaceutical industry. In October 2009, our company began voluntarily disclosing all payments to U.S.-based health care professionals who speak on behalf of our company, about our products and other health care issues.

Updated reports are posted annually reflecting payments and transfers of value to U.S.-based physicians, including those engaged in clinical research activities. We included both direct payments to individual physicians, as well as “indirect” payments to the research entity/institution with the name of the associated principal investigator(s). The latter does not imply a direct payment to the individuals but rather support for the work that they are doing in the context of the research on behalf of their entity/institution.

We comply with the PPSA provisions of the U.S. Affordable Care Act, which requires pharmaceutical manufacturers to annually disclose information on certain additional payments and other transfers of value furnished to U.S.-licensed physicians and U.S. teaching hospitals to the Department of Health and Human Services (HHS). In addition to submitting such information to HHS’s Center for Medicare & Medicaid Services each year, we will post the information annually on this website.

For information regarding payments made to U.S.-based health care professionals by Cubist Pharmaceuticals, now a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, please choose a link below.

The Importance of Engaging with Medical and Scientific Leaders within the United States

We engage with health care professionals around the world to conduct company-sponsored clinical studies on the safety and effectiveness of our products. We conduct these studies in accordance with strict regulatory requirements with “real world” physicians and their patients in order to learn more about our products and bring new medicines and vaccines to patients who need them. Once a product is approved for marketing, we continue to conduct studies in order to monitor ongoing safety and effectiveness.

We also engage with health care professionals through our Investigator Studies Program (MISP), whose mission is to advance the delivery of quality health care by supporting investigator-initiated original research that will enhance the understanding of disease entities and their treatment. This program is open to all academic and community-based physicians and researchers worldwide who are interested in conducting their own research.

We are committed to the discovery and development of important new drugs and vaccines through collaboration with scientific leaders from academic and scientific organizations from around the world. Advice in the form of consulting engagements with external medical and scientific experts results in meaningful, scientific exchanges that bring real-world knowledge and perspectives to our company. These critical exchanges contribute to advancing science both at our company and in the broader scientific community, and ultimately help benefit human health. We also engage physicians as speakers in the U.S. through our company’s Medical Forums, which are designed to deliver balanced medical and scientific information to health care professionals so that patients can have access to the medicines and vaccines they need and use these products correctly. These programs are structured to be consistent with the PhRMA Code on Interactions with Healthcare Professionals and are conducted in compliance with FDA regulations to help ensure that our product information is presented in an appropriately balanced manner, with respect to potential benefits and risks.